Business
Conavi Medical Announces Results from Its Annual General Meeting of Shareholders
TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (&#...
About this update from Conavi Medical Corp.
[{"type":"text","content":"Conavi Medical Announces Results from Its Annual General Meeting of Shareholders\nTORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, announced today the results of its annual general meeting of shareholders held virtually on March 31, 2026 (the “Meeting”), as well as the adoption of amendments to the Company’s Stock Option Plan. A total of 54,352,402 common shares were voted in connection with the Meeting, representing approximately 52.56% of the issued and outstanding common shares of the Company. Each of the seven nominees listed in the management information circular of the Company (the “Circular”) dated February 17, 2026, namely, Thomas Looby, Aaron Davidson, Craig Podolsky, Robert D. Mitchell, Susan Allen, Cathy Steiner and Anthony J. Giovinazzo, was elected as a director of the Company for the ensuing year or until his or her successor is elected or appointed (with at least 98.5% of votes cast voting in favour for each director). In addition, Conavi Medical reports that an ordinary resolution approving the appointment of PricewaterhouseCoopers LLP as the Company’s auditors for the ensuing year and to authorize the directors to fix the auditors’ remuneration was passed at the Meeting (with 99.49% of votes cast voting in favour). Further, an ordinary resolution of shareholders of the Company was passed (with 97.57% of votes cast voting in favour) approving the amendment of the Company’s Omnibus Equity Incentive Plan in order to increase the aggregate number of common shares that may be issued thereunder to not more than 18,187,372 common shares. The Company is increasing the number of shares available for issuance in the Omnibus Equity Incentive Plan given the Company’s expanded capitalization following its public offerings completed in April 2025 and January 2026, and the Company believes this will provide greater flexibility to continue to attract, retain and motivate directors and executive officers, while providing room for future growth. Following this increase, the number of ...